⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 15, 2024Open Access

Supplementary Figure S1 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients

Funda Meric‐Bernstam Antoine Hollebecque Junji Furuse Do‐Youn Oh John Bridgewater Masashi Shimura Bailey Anderson Nanae Hangai Volker Wacheck Lipika Goyal

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Safety analysis populations

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2a2b6db64358766d0cc https://doi.org/10.1158/1078-0432.25603770.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients2024
2Data from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients2024
3Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients2024 · 20 citations
4Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) databaseOriginal Research · 2026
5Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis.Original Research · 2026